ATE449859T1 - Virusvektor zur gentherapie - Google Patents

Virusvektor zur gentherapie

Info

Publication number
ATE449859T1
ATE449859T1 AT02727029T AT02727029T ATE449859T1 AT E449859 T1 ATE449859 T1 AT E449859T1 AT 02727029 T AT02727029 T AT 02727029T AT 02727029 T AT02727029 T AT 02727029T AT E449859 T1 ATE449859 T1 AT E449859T1
Authority
AT
Austria
Prior art keywords
gene therapy
virus vector
infectivity
type
adenovirus
Prior art date
Application number
AT02727029T
Other languages
English (en)
Inventor
Goeran Wadell
Ya-Fang Mei
Anna Segerman
Johan Skog
Kristina Lindman
Original Assignee
Goeran Wadell
Ya-Fang Mei
Anna Segerman
Johan Skog
Kristina Lindman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26655363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE449859(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0100035A external-priority patent/SE0100035D0/xx
Application filed by Goeran Wadell, Ya-Fang Mei, Anna Segerman, Johan Skog, Kristina Lindman filed Critical Goeran Wadell
Application granted granted Critical
Publication of ATE449859T1 publication Critical patent/ATE449859T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02727029T 2001-01-04 2002-01-04 Virusvektor zur gentherapie ATE449859T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0100035A SE0100035D0 (sv) 2001-01-04 2001-01-04 Viral vectors for gene therapy
US26035801P 2001-01-08 2001-01-08
PCT/SE2002/000013 WO2002053759A1 (en) 2001-01-04 2002-01-04 Viral vector for gene therapy

Publications (1)

Publication Number Publication Date
ATE449859T1 true ATE449859T1 (de) 2009-12-15

Family

ID=26655363

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02727029T ATE449859T1 (de) 2001-01-04 2002-01-04 Virusvektor zur gentherapie

Country Status (6)

Country Link
US (1) US7459153B2 (de)
EP (1) EP1348030B1 (de)
AT (1) ATE449859T1 (de)
AU (1) AU2002217721A1 (de)
DE (1) DE60234496D1 (de)
WO (1) WO2002053759A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1497440B1 (de) 2002-04-25 2008-08-20 Crucell Holland B.V. Stabile adenovirale vektoren und methoden für deren vermehrung
JP4237449B2 (ja) * 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20050036989A1 (en) * 2003-07-18 2005-02-17 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
BRPI0510475B8 (pt) 2004-05-26 2021-05-25 Bayer Pharma AG adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
WO2008080003A2 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
WO2011032100A1 (en) 2009-09-11 2011-03-17 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Inhibitors of kshv vil6 and human il6
WO2011043719A1 (en) * 2009-10-05 2011-04-14 Ya-Fang Mei Replicating viral vectors for gene therapy
EP2916874B1 (de) * 2012-11-07 2018-08-29 Council of Scientific and Industrial Research Nanokomplex mit kationischen peptiden zur biomolekülabgabe
HUE035875T2 (hu) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
BR112018012180A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054467A (en) * 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis
US6555367B1 (en) * 1997-10-10 2003-04-29 The United States Of America As Represented By The Department Of Health And Human Services Complex of biotinylated viral vector and ligand for targeted gene delivery
ES2372823T3 (es) 1999-05-17 2012-01-26 Crucell Holland B.V. Adenovirus recombinante del serotipo ad11.
US6524572B1 (en) * 2000-06-26 2003-02-25 Rainbow Therapeutic Company Targeting recombinant virus with a bispecific fusion protein ligand in coupling with an antibody to cells for gene therapy

Also Published As

Publication number Publication date
WO2002053759A9 (en) 2007-10-11
AU2002217721A1 (en) 2002-07-16
EP1348030A1 (de) 2003-10-01
US7459153B2 (en) 2008-12-02
AU2002217721A8 (en) 2007-12-06
WO2002053759A1 (en) 2002-07-11
US20040136958A1 (en) 2004-07-15
EP1348030B1 (de) 2009-11-25
DE60234496D1 (de) 2010-01-07

Similar Documents

Publication Publication Date Title
DE60234496D1 (de) Virusvektor zur gentherapie
Lubotzky et al. Explicit constructions of Ramanujan complexes of type Ad
IS7896A (is) Latar á lifrarbólgu C vírus ríbósakjarnsýru-háðu ríbósakjarnsýru liðunarensími, og samsetningar og meðferðir sem nota þá.
WO2000050088A3 (en) Biotinylated-chemokine antibody complexes
NL1021701A1 (nl) PEM-brandstofcel.
GB0303188D0 (en) An herpes simplex virus complex
ATE373081T1 (de) Zelllinie
ZA200207704B (en) Multi-stage combustion for fuel processing for use with fuel cell.
DE60140802D1 (de) Immuntoxin-fusionsproteine und mittel zu deren expression
WO2002079419A3 (en) Identifying and characterizing genes
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
AU306519S (en) Point of sale terminal
WO2003029453A3 (en) Induction of gene expression by silencing of repressor genes
CA2529001A1 (en) Binding peptides: methods for their generation and use
WO2007050405A3 (en) The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof
EP1462113A4 (de) ZELLWACHSTUMSHEMMER MIT ANTI-PepT-ANTIKÖRPER
WO2003038037A3 (en) Glycogen synthase kinase function in endothelial cells
CA110297S (en) Wick clip
ZA99445B (en) Isolated, polypeptides which bind to HLA-A29 molecules nucleic acid, the molecules encoding these, and uses thereof.
MXPA03001884A (es) Agregados de proteina vp22/acido nucleico y uso de los mismos.
DE50113417D1 (de) Zellbindende nukleinsäuremoleküle (aptamere)
Lobo Primary lead and zinc boosted in India
Xia et al. Research on the simulation of lwd curves and its geosteering application
TW200628798A (en) Testing probe
Stephens Performance Based Qualification: A Way to Increase NDT Reliability

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties